Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2025 | Press briefing: results from the ACCESS trial

Antonio Jimenez-Jimenez • 7 Dec 2025
ASH 2025
General Leukemia Cyclophosphamide

In this press briefing, Antonio Jimenez-Jimenez, MD, Sylvester Comprehensive Cancer Center, Miami, FL, presents findings from the ACCESS trial (NCT04904588) evaluating whether the degree of donor-recipient HLA disparity impacts stem cell transplantation outcomes in patients with hematologic malignancies. This press briefing took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
1:30
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
Antonio Jimenez-Jimenez • 7 Dec 2025
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
0:53
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
Antonio Jimenez-Jimenez • 7 Dec 2025
Results of the ASC2ESCALATE trial of asciminib in CML-CP with one prior TKI
2:34
Results of the ASC2ESCALATE trial of asciminib in CML-CP with one prior TKI
Antonio Jimenez-Jimenez • 7 Dec 2025
Asciminib in patients with CML-CP who have not achieved DMR after ≥1 year of imatinib: ASC4MORE
2:15
Asciminib in patients with CML-CP who have not achieved DMR after ≥1 year of imatinib: ASC4MORE
Antonio Jimenez-Jimenez • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals